产品

您的位置:首页 > 食品资讯 > 外讯导读 > 欧盟评估转基因紫红链霉菌菌株pCol生产的微生物胶原酶的安全性

欧盟评估转基因紫红链霉菌菌株pCol生产的微生物胶原酶的安全性

来源:好招商食品网 外讯导读   |  2024-04-25
   好招商食品网讯  2024年2月23日,欧盟食品安全局就一种食品酶微生物胶原酶(microbial collagenase)的安全性评价发布意见。
 
  据了解,这种食品酶是由转基因紫红链霉菌菌株pCol生产的,旨在用于生产改良的肉类和鱼类产品以及从肉类和鱼类蛋白质中生产蛋白质水解产物。
 
  经过评估,专家小组认为,在预期的使用条件下,不能排除通过饮食接触引起过敏反应的风险,但这种情况发生的可能性很低。根据所提供的数据,小组得出结论,该食品酶在预期的使用条件下不会引起安全问题。部分原文报道如下:
 
  The food enzyme microbial collagenase (EC 3.4.24.3) is produced with the genetically modified Streptomyces violaceoruber strain pCol by Nagase (Europa) GmbH. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and its DNA. It is intended to be used in two food manufacturing processes: the production of modified meat and fish products and the production of protein hydrolysates from meat and fish proteins. The dietary exposure to the food enzyme–total organic solids (TOS) was estimated to be up to 1.098 mg TOS/kg body weight (bw) per day in European populations. Genotoxicity tests did not indicate a safety concern. The systemic toxicity was assessed by means of a repeated dose 90-day oral toxicity study in rats. The Panel identified a no observed adverse effect level of 940 mg TOS/kg bw per day, the highest dose tested, which, when compared with the estimated dietary exposure, resulted in a margin of exposure of at least 856. A search for the similarity of the amino acid sequence of the food enzyme to known allergens was made and no match was found. The Panel considered that the risk of allergic reactions by dietary exposure cannot be excluded, but the likelihood is low. based on the data provided, the Panel concluded that this food enzyme does not give rise to safety concerns, under the intended conditions of use.
 

TAGS:食品 安全局 转基因 霉菌 微生物
免责声明:本站部分文章转载自网络,图文仅供行业学习交流使用,不做任何商业用途。文章仅代表原作者个人观点,其原创性及文章内容中图文的真实性、完整性等未经本站核实,仅供读者参考。
上一篇: 欧盟评估由羟丙基甲基纤维素和甲基纤维素组成的饲料添加剂对所有动物的安全性
下一篇: 欧盟评估转基因黑曲霉菌株NPH生产的3-植酸酶的安全性